

Cover Story
Free
After a five-year investigation, the HHS Office of Research Integrity announced that it has settled with former Duke University researcher Anil Potti.
In Brief


Drugs & Targets
Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- From the chairs of ECOG-ACRIN: A perspective on indirect costs
- On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty - FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns”